SPHK2 and cancer: Specifically, the results from a recent phase 1 cancer clinical trial for the SphK2 inhibitor ABC294640 strongly supported the use of SphK2 inhibitor as an anticancer treatment [200], positively demonstrating ABC294640 pharmacologic inhibition of SK2 resulted in clear anticancer activity [200].